UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
-------------------------------
SEC FILE NUMBER
0-21022
-------------------------------
CUSIP NUMBER
819319 50 0
-------------------------------
(CHECK ONE): [x] Form 10-K [ ] Form 11-K [ ] Form 20-F
[ ] Form 10-Q [ ] Form N-SAR
For Period Ended: December 31, 2000
--------------------------------------------
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended:
-----------------------------
If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:
------------------------------------------------------------------------------
PART I - REGISTRANT INFORMATION
------------------------------------------------------------------------------
Full Name of Registrant: Shaman Pharmaceuticals, Inc.
------------------------------------------------------------------------------
Former name if applicable: Not Applicable
------------------------------------------------------------------------------
Address of Principal Executive Office
(Street and Number): 213 East Grand Avenue
------------------------------------------------------------------------------
City, State and Zip Code: South San Francisco, CA 94080
------------------------------------------------------------------------------
PART II - RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate)
[x] (a) The reasons described in reasonable detail in Part III of this
form could not be eliminated without unreasonable effort or expense;
[x] (b) The subject annual report, semi-annual report, transition
report on Form 10-K, Form 20-F, Form 11-K or Form N-SAR, or portion thereof,
will be filed on or before the fifteenth calendar day following the
prescribed due date; or the subject quarterly report or transition report on
Form 10-Q, or portion thereof, will be filed on or before the fifth calendar
day following the prescribed due date; and
[x] (c) The accountant's statement or other exhibit required by
Rule 12b-25(c) has been attached if applicable.
PART III - NARRATIVE
State below in reasonable detail the reasons why the Form 10-K, 20-F, 11-K,
10-Q, N-SAR or the transition report or portion thereof, could not be filed
within the prescribed time period.
Shaman Pharmaceuticals, Inc. (the "Registrant") is unable to timely file its
Annual Report on Form 10-K for the year ended December 31, 2000, without
unreasonable effort or expense. The delay is principally because of the
Registrant's Chapter 11 Bankruptcy filing and substantial management focus on
reorganization efforts resulting in reduced company resources. Due to the
lack of personnel of the Registrant to compile financial information for the
audit, BDO Seidman, LLP, the independent auditors of the Registrant, has not
yet completed the audit of the financial statements of the Registrant for the
year ended December 31, 2000 and cannot furnish the required opinion on such
financial statements until it has completed its audit.
PART IV - OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification:
Lisa A. Conte (650) 266-7466
----------------------------------- -----------------------------------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 of 15(d) of the
Securities exchange Act of 1934 or Section 30 of the Investment Company Act
of 1940 during the preceding 12 months (or for such shorter period that the
registrant was required to file such report(s)) been filed? If the answer is
no, identify report(s). [x] Yes [ ] No
(3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be reflected by
the earnings statements to be included in the subject report or portion
thereof? [ ]Yes [x] No
If so: attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
2
Shaman Pharmaceuticals, Inc.
-------------------------------------
(Name of Registrant as specified in charter)
has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: March 30, 2001
-------------------------------------
By: /s/ Lisa A. Conte
---------------------------------------
Lisa A. Conte
President, Chief Executive Officer and
Chief Financial Officer of Registrant
3